The preliminary efficacy and safety data of KN046 in patients failed on prior immune checkpoint inhibitors therapy.

Hongyun Zhao,Yuxiang Ma,Yang Zhang,Shaodong Hong,Yunpeng Yang,Wenfeng Fang,June Xu,Hardy Van,Paul Kong,Fei Yang,Jingying Li,Yao Lu,Li Zhang

The preliminary efficacy and safety data of KN046 in patients failed on prior immune checkpoint inhibitors therapy.

2020

Hongyun Zhao
Yuxiang Ma
Yang Zhang
Shaodong Hong
Yunpeng Yang
Wenfeng Fang
June Xu
Hardy Van
Paul Kong
Fei Yang
Jingying Li
Yao Lu
Li Zhang

3020Background: KN046 is a bispecific antibody that blocks PD-L1 and CTLA-4 by interaction with PD1 and CD80/CD86. KN046-CHN-001 (NCT03529526) is a, dose escalation and expansion phase Ia/Ib clinic...

Keywords:

Oncology
in patient
Pathology
Internal medicine
immune checkpoint inhibitors
Medicine
CD86
expansion phase
CD80
dose escalation
bispecific antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations